Loading...
Biomx Inc (PHGE) is set to release its earnings performance on 08/13 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of - and an earnings per share (EPS) of -0.33 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings call highlighted significant financial challenges, including a substantial net loss and a declining cash balance. Despite some positive developments, such as potential DHA support and FDA feedback, the financial health concerns and lack of clear guidance on critical issues, like the nebulizer hold, overshadowed these positives. The Q&A revealed management's vague responses, especially regarding the Phase III study for BX004, contributing to uncertainty. These factors, combined with the operational reductions and financial risks, suggest a likely negative impact on the stock price.
The earnings call presents a mixed picture: positive trial results and strong interest in BX004, but with significant regulatory and market risks. Financial metrics show decreased losses and cash usage, but the net cash position is declining. The Q&A highlights enthusiasm for BX004 but also reveals management's reluctance to provide specific timelines, suggesting uncertainty. Without clear guidance or new partnerships, and considering the absence of a market cap, the stock price is likely to remain stable, leading to a neutral sentiment.
The earnings call indicates positive developments, such as ongoing clinical trials and financing to support operations until 2026. However, there are significant risks, including regulatory uncertainties and financial sufficiency concerns. The Q&A section highlighted unclear responses from management, contributing to uncertainty. Although the company is addressing unmet needs, the lack of immediate catalysts and the absence of a market cap suggest a neutral stock price movement in the short term.
The earnings call presents a mixed picture. Financially, the company has decreased its net loss and improved cash management, but there are ongoing financial challenges and reliance on external funding. Regulatory risks and competitive pressures in the DFO market remain significant concerns. The Q&A reveals some uncertainty in regulatory interactions and study designs, which could affect investor sentiment. However, the $12 million financing and non-diluted funding from the U.S. Defense Health Agency are positives. Overall, the stock price is likely to remain stable, leading to a neutral prediction.
Biomx Inc (PHGE) is scheduled to release its FY2025Q2 earnings report onAug 13, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 0.00 in revenue and an EPS of -0.33 for Biomx Inc's FY2025Q2.
Intellectia's exclusive AI algorithms forecast a forBiomx Inc's FY2025Q2 earnings, with a prediction date of Aug 13, 2025. Biomx Inc
Leverage Intellectia's AI forecast to position trades ahead of theAug 13, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!